Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00328627 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,554
- Enrollment target
NCT00328627 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,554 participants.
The verdict
NCT00328627, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,554 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.
Interventions
- DRUG Pioglitazone
- DRUG Alogliptin
- DRUG Pioglitazone placebo
- DRUG Alogliptin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,554 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00328627
The ClinicalTrials.gov registry entry for NCT00328627 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,554 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pioglitazone is the first listed.
NCT00328627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00328627 about?
NCT00328627 is a clinical study titled "Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.". The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.
What is the current status of trial NCT00328627?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,554 participants. The study started on 2006-05. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00328627?
The interventions under investigation include: Pioglitazone (DRUG), Alogliptin (DRUG), Pioglitazone placebo (DRUG), Alogliptin placebo (DRUG).
Who is sponsoring clinical trial NCT00328627?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.